HUBUNGAN FREKUENSI AKTIVITAS SEKSUAL DENGAN DERAJAT HISTOPATOLOGI KANKER PROSTAT
DOI:
https://doi.org/10.62710/t0njar59Keywords:
Derajat Histopatologi, Frekuensi Aktivitas Seksual, ISUP Grade Group, Kanker ProstatAbstract
Derajat histopatologi menentukan agresivitas kanker prostat, tetapi hubungannya dengan frekuensi aktivitas seksual pada pasien yang telah terdiagnosis belum banyak diteliti. Penelitian ini bertujuan menganalisis hubungan frekuensi aktivitas seksual dengan derajat histopatologi kanker prostat. Penelitian observasional analitik dengan desain potong lintang retrospektif ini melibatkan 95 pasien adenokarsinoma prostat terkonfirmasi histopatologi di RS Royal Prima dan RSUD Dr. Pirngadi Medan yang dipilih secara accidental sampling. Derajat histopatologi diperoleh dari rekam medis dan dikelompokkan menurut ISUP Grade Group 1–5, sedangkan frekuensi aktivitas seksual diperoleh melalui kuesioner dan dikategorikan rendah, sedang, dan tinggi. Data dianalisis dengan regresi logistik ordinal dengan usia sebagai variabel kontrol. Frekuensi rendah merupakan kategori terbanyak (45,3%), dan ISUP Grade Group 5 merupakan derajat terbanyak (40,0%). Setelah dikontrol usia, frekuensi aktivitas seksual berhubungan bermakna dengan ISUP Grade Group (p=0,011). Dibandingkan frekuensi tinggi, frekuensi rendah memiliki odds 8,35 kali lebih besar untuk berada pada kategori ISUP yang lebih tinggi (IK 95% 2,05–33,92), dengan estimasi yang belum presisi. Frekuensi sedang tidak berbeda bermakna dari frekuensi tinggi (p=0,082). Hasil ini menunjukkan asosiasi statistik, bukan hubungan sebab-akibat, dan tidak dapat ditafsirkan sebagai risiko terjadinya kanker prostat.
Downloads
References
Altman, D. G., & Bland, J. M. (1995). Absence of evidence is not evidence of absence. BMJ, 311(7003), 485. https://doi.org/10.1136/bmj.311.7003.485
Amelia, D. A. R., & Putra, R. (2025). Prostate cancer clinical characteristics and systemic inflammatory indices at RSUD Ciawi in 2023, a preliminary study from a secondary referral hospital. Indonesian Journal of Biomedicine and Clinical Sciences, 57(3, Suppl.), 19. https://doi.org/10.22146/inajbcs.v57i3.Supplement.24549
Archer, M., Dogra, N., & Kyprianou, N. (2020). Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers, 12(10), Article 2984. https://doi.org/10.3390/cancers12102984
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016). The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. The American Journal of Surgical Pathology, 40(2), 244–252. https://doi.org/10.1097/PAS.0000000000000530
Esfandiary, P. R., Safriadi, F., & Mustafa, A. (2026). Correlation of age, PSA value, Gleason score, and staging with metastasis in prostate cancer. Majalah Kedokteran Bandung, 58(1), 83–88. https://doi.org/10.15395/mkb.v58.4225
Hassan, M., Flanagan, T. W., Eshaq, A. M., Altamimi, O. K., Altalag, H., Alsharif, M., Alshammari, N., Alkhalidi, T., Boulifa, A., El Jamal, S. M., Haikel, Y., & Megahed, M. (2025). Reduction of prostate cancer risk: Role of frequent ejaculation-associated mechanisms. Cancers, 17(5), Article 843. https://doi.org/10.3390/cancers17050843
Herawan, M. I. A. K., & Adriansjah, R. (2024). Prostate specific antigen level and Gleason score in Indonesian prostate cancer patients. Majalah Kedokteran Bandung, 56(3), 209–213. https://doi.org/10.15395/mkb.v56.3571
Jian, Z., Ye, D., Chen, Y., Li, H., & Wang, K. (2018). Sexual activity and risk of prostate cancer: A dose–response meta-analysis. The Journal of Sexual Medicine, 15(9), 1300–1309. https://doi.org/10.1016/j.jsxm.2018.07.004
Leitzmann, M. F., Platz, E. A., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2004). Ejaculation frequency and subsequent risk of prostate cancer. JAMA, 291(13), 1578–1586. https://doi.org/10.1001/jama.291.13.1578
Lemeshow, S., Hosmer, D. W., Klar, J., & Lwanga, S. K. (1990). Adequacy of sample size in health studies. John Wiley & Sons.
Lozano-Lorca, M., Olmedo-Requena, R., Barrios-Rodríguez, R., Jiménez-Pacheco, A., Vázquez-Alonso, F., Castillo-Bueno, H.-M., Rodríguez-Barranco, M., & Jiménez-Moleón, J. J. (2023). Ejaculation frequency and prostate cancer: CAPLIFE study. The World Journal of Men’s Health, 41(3), 724–733.
Melão, B. V. L. A., Pekala, K. R., Matsoukas, K., Bratt, O., & Carlsson, S. V. (2025). SIU-ICUD: Epidemiology of prostate cancer. Société Internationale d’Urologie Journal, 6(3), Article 44. https://doi.org/10.3390/siuj6030044
Papa, N. P., MacInnis, R. J., English, D. R., Bolton, D., Davis, I. D., Lawrentschuk, N., Millar, J. L., Pedersen, J., Severi, G., Southey, M. C., Hopper, J. L., & Giles, G. G. (2017). Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study. Urologic Oncology: Seminars and Original Investigations, 35(8), 530.e7–530.e13. https://doi.org/10.1016/j.urolonc.2017.03.007
Raeisvandi, A., Omidi, S., Javaheri, M., Moradi, H., & Poorolajal, J. (2026). Updated dose–response meta-analysis of sexual activity and prostate cancer risk. BMC Cancer, 26(1), Article 47. https://doi.org/10.1186/s12885-025-15410-3
Rider, J. R., Wilson, K. M., Sinnott, J. A., Kelly, R. S., Mucci, L. A., & Giovannucci, E. L. (2016). Ejaculation frequency and risk of prostate cancer: Updated results with an additional decade of follow-up. European Urology, 70(6), 974–982. https://doi.org/10.1016/j.eururo.2016.03.027
Safriadi, F., & Novesar, A. R. (2021). Five-year profiles of prostate cancer patients in a tertiary hospital in Indonesia. Majalah Kedokteran Bandung, 53(2), 101–106. https://doi.org/10.15395/mkb.v53n2.2212
Song, W., Kim, J. S., & Ko, K. J. (2023). Baseline lower urinary tract symptoms and sexual dysfunction in men with newly diagnosed localized prostate cancer. Journal of Clinical Medicine, 12(13), Article 4462. https://doi.org/10.3390/jcm12134462
Taborelli, M., Serraino, D., Toffolutti, F., Bidoli, E., De Vidi, S., Fratino, L., & Dal Maso, L. (2025). Trends in prostate cancer incidence and survival by Gleason score from 2000 to 2020: A population-based study in northeastern Italy. Current Oncology, 32(8), Article 426. https://doi.org/10.3390/curroncol32080426
van Leenders, G. J. L. H., van der Kwast, T. H., Grignon, D. J., Evans, A. J., Kristiansen, G., Kweldam, C. F., Litjens, G., McKenney, J. K., Melamed, J., Mottet, N., Paner, G. P., Samaratunga, H., Schoots, I. G., Simko, J. P., Tsuzuki, T., Varma, M., Warren, A. Y., Wheeler, T. M., Williamson, S. R., & Iczkowski, K. A. (2020). The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. The American Journal of Surgical Pathology, 44(8), e87–e99. https://doi.org/10.1097/PAS.0000000000001497
Wasserstein, R. L., & Lazar, N. A. (2016). The ASA statement on p-values: Context, process, and purpose. The American Statistician, 70(2), 129–133. https://doi.org/10.1080/00031305.2016.1154108
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jurnal Ilmu Kesehatan & Kebidanan Nusantara
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
